Last reviewed · How we verify
Clarithromycin 250 MG
Clarithromycin 250 MG is a Small molecule drug developed by The University of Hong Kong. It is currently FDA-approved. Also known as: Klacid Syrup® Forte 250 mg/5mL.
Clarithromycin 250 MG is a small molecule used to treat conditions such as gastric low-grade MALT lymphoma with Helicobacter pylori positive, sepsis, severe sepsis, and septic shock. It is administered as part of a treatment regimen that may include other medications like Rabeprazole Sodium and Dextrose 5%.
At a glance
| Generic name | Clarithromycin 250 MG |
|---|---|
| Also known as | Klacid Syrup® Forte 250 mg/5mL |
| Sponsor | The University of Hong Kong |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
- Efficacy of Long-Term Low Dose Macrolide Therapy in Preventing Early Recurrence of Nasal Polyps After Endoscopic Sinus Surgery (NA)
- CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections (PHASE3)
- Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
- Tailored Vs. Empirical Helicobacter Pylori Infection Treatment (PHASE4)
- Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies (PHASE1)
- Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clarithromycin 250 MG CI brief — competitive landscape report
- Clarithromycin 250 MG updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI
Frequently asked questions about Clarithromycin 250 MG
What is Clarithromycin 250 MG?
Who makes Clarithromycin 250 MG?
Is Clarithromycin 250 MG also known as anything else?
What development phase is Clarithromycin 250 MG in?
Related
- Manufacturer: The University of Hong Kong — full pipeline
- Also known as: Klacid Syrup® Forte 250 mg/5mL
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing